A study of 114 platinum‐pretreated patients (PPP cohort) with metastatic NSCLC and EGFR ex20ins treated with 160 mg/day of mobocertinib (combining a dose escalation study, an expansion study in seven molecularly and histologically defined expansion cohorts, and an extension study) reported an independent review committee (IRC)‐assessed confirmed objective response rate of 28% and a median IRC‐assessed PFS of 7.3 months (95% confidence interval [CI]: 5.5, 9.2) [14]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.